OOIR: Observatory of International Research

Papers

(The H4-Index of Trends in Pharmacological Sciences is 49. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)

Article	Citations
Subscription and Copyright Information	690
Subscription and Copyright Information	445
Subscription and Copyright Information	277
Subscription and Copyright Information	183
Advisory Board and Contents	174
Structural asymmetry in FGF23 signaling	162
Subscription and Copyright Information	161
DOT1L: orchestrating methylation-dependent radiotheRAPy responses via BRCA1	153
Assembling the P450 puzzle: on the sources of nonadditivity in drug metabolism	146
Muscarinic receptors: from clinic to bench to clinic	139
Shearing of surface mucin saps tumor cell strength	136
Monitoring neurodegeneration through brain-derived extracellular vesicles in biofluids	122
Targeting of Potassium Channels in Cardiac Arrhythmias	111
Direct in vivo CAR T cell engineering	107
Structural pharmacology and mechanisms of GLP-1R signaling	107
Targeting complement in neurodegeneration: challenges, risks, and strategies	101
Advancing chemical carcinogenicity prediction modeling: opportunities and challenges	95
Compstatins: the dawn of clinical C3-targeted complement inhibition	94
Ensifentrine (Ohtuvayre™) for chronic obstructive pulmonary disease	93
Peptides as a therapeutic strategy against Klebsiella pneumoniae	87
Therapeutic inhibition of ferroptosis in neurodegenerative disease	84
Advisory Board and Contents	81
Advisory Board and Contents	81
Chemically modified neoantigen-based immunotherapy for targeting KRASG12C-driven tumors	79
Phenotypic approaches for CNS drugs	75

A smart hospital-driven approach to precision pharmacovigilance	72
HSV-1 as a gene delivery platform for cancer gene therapy	72
Ribosome-directed cancer therapies: the tip of the iceberg?	68
Advisory Board and Contents	65
A deep dive into degrader-induced protein-protein interfaces	63
Leveraging human microbiomes for disease prediction and treatment	62
siRNA drug Leqvio (inclisiran) to lower cholesterol	60
Mechanistic considerations for adenosine-lidocaine-magnesium (ALM) in controlling coagulopathy	60
Emerging strategies for beta cell transplantation to treat diabetes	60
Genetically engineered loaded extracellular vesicles for drug delivery	58
Liquid–liquid phase separation: a principal organizer of the cell’s biochemical activity architecture	58
Engineering ACE2 decoy receptors to combat viral escapability	57
A perspective on psychedelic teratogenicity: the utility of zebrafish models	57
Advisory Board and Contents	57
Suzetrigine for moderate to severe acute pain	55
Targeting AMPK as a potential treatment for hepatic fibrosis in MASLD	55
Selective tyrosine kinase 2 inhibitors in inflammatory bowel disease	52
Close to a year in TIPS’ saddle – I am optimistic	52
Subscription and Copyright Information	52
Thriving as members of under-represented groups in pharmacology-related careers	51
Lipoxygenases in chronic liver diseases: current insights and future perspectives	50
Alzheimer’s therapeutic development: shifting neurodegeneration to neuroregeneration	49
Therapeutic Potential of Targeting Plasminogen Activator Inhibitor-1 in COVID-19	49
Could dexmedetomidine be repurposed as a glymphatic enhancer?	49